Company

HBM Holdings Ltd

Headquarters: Shanghai, China

CEO: Dr. Jingsong Wang M.D., Ph.D.

HKEX: 2142

Market Cap

HK$962.2 Million

HKD as of July 1, 2024

US$123.2 Million

Market Cap History

HBM Holdings Ltd market capitalization over time

Evolution of HBM Holdings Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of HBM Holdings Ltd

Detailed Description

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9001 for the treatment of asthma; HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

HBM Holdings Ltd has the following listings and related stock indices.


Stock: HKEX: 2142 wb_incandescent

Details

Headquarters:

Tower A, 12th Floor

Fenglin International Plaza Phase II 420 Fenglin Road Xuhui District

Shanghai, 200032

China

Phone: 86 21 5339 9123